Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
FiercePharma  Jan 9  Comment 
Japanese drugmaker Daiichi Sankyo will pay the $39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to prescribe some of its drugs, Reuters reports.
FiercePharma  Jan 9  Comment 
What's long been a three-horse race just gained a fourth horse with the FDA's green light for Daiichi Sankyo's clot-fighter Savaysa. With the FDA's Thursday blessing, the drug will now face down a new-age anticoagulant trifecta that's been duking...
MedPage Today  Jan 9  Comment 
(MedPage Today) -- But agency limits use in Afib and VTE.
FierceBiotech  Jan 9  Comment 
The FDA signed off on Daiichi Sankyo's clot-preventing edoxaban, giving the Japanese drugmaker the green light to compete in a crowded market for next-generation anticoagulants.
Forbes  Oct 31  Comment 
On Thursday the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo's edoxaban (Savaysa), but the outcome will likely result in a drug that will be on the market but that few physicians will...
FierceBiotech  Oct 30  Comment 
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
FierceBiotech  Oct 28  Comment 
Daiichi Sankyo's campaign to win approval for its atrial fibrillation drug edoxaban gained some support from regulators at the FDA who were clearly won over by the efficacy data in the NDA. But the internal review of the drug also includes...
DailyFinance  Sep 29  Comment 
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit...
DailyFinance  Sep 29  Comment 
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ambit Biosciences...





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki